ARIAD Pharma (ARIA) Announces Publication of Brigatinib Phase 1/2 Data; Median PFS Observed at 1+ Year

November 9, 2016 7:41 AM EST

Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.

ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) announced clinical data on its investigational anaplastic lymphoma kinase (ALK) inhibitor, brigatinib, were published in The Lancet Oncology (Gettinger, S.; ed al. The Lancet Onc. 2016, DOI: 10.1016/S1470-2045(16)30392-8 Published 8 November 2016). ARIAD has submitted a New Drug Application (NDA) for brigatinib to the U.S. Food and Drug Administration (FDA), seeking U.S. marketing approval for patients with metastatic ALK-positive (ALK+) non-small cell lung cancer (NSCLC) who are resistant or intolerant to crizotinib.

“The publication reports the results of the first clinical evaluation of brigatinib in patients with advanced malignancies, including ALK+ NSCLC,” stated Scott N. Gettinger, M.D., associate professor of medicine at Yale Cancer Center and lead author. “Brigatinib yielded responses in the majority of patients with crizotinib-treated ALK+ NSCLC, with median progression free survival of over one year. Additionally, responses in the brain were achieved in this crizotinib refractory population. Early onset pulmonary adverse events, which occurred in eight percent of patients, generally within 48 hours of first dose, appeared to be related to starting dose.”

The data published this week include safety analyses on all patients in the trial (N=137) and efficacy analyses on all patients with ALK+ NSCLC (n=79). Of the 79 ALK+ NSCLC patients, all but eight had previously been treated with crizotinib. With patient data as of June 2015, the median time on treatment for ALK+ NSCLC patients was 15.4 months (range, 0.03 – 39.4 months, ongoing).

The confirmed objective response rate (ORR) was 62% (44/71) in ALK+ NSCLC patients with prior crizotinib treatment. The median progression free survival (PFS) of ALK+ NSCLC patients previously treated with crizotinib was 13.2 months. Eight ALK+ NSCLC patients in the trial were crizotinib-naive. Of these, all eight achieved a confirmed objective response, including three complete responses. At the time of analysis, median PFS was not reached in these patients. Brain metastases were identified in 63% of ALK+ NSCLC patients (50/79) at baseline. The intracranial ORR was 53% (8/15) among evaluable patients with measurable brain metastases.

The most common grade 3–4 treatment-emergent adverse events across all doses were increased lipase (9%; 12/137), dyspnea (6%; 8/137), and hypertension (5%; 7/137). Serious treatment-emergent adverse events (excluding neoplasm progression) reported in ≥5% of all patients were dyspnea (7%; 10/137), pneumonia (7%; 9/137), and hypoxia (5%; 7/137). Eight percent of patients (11/137) experienced a subset of pulmonary adverse events with early onset, most occurring within 48 hours of dosing. The frequency of these events appeared dose-related. Among patients who started at 90 mg once daily and continued at this dose or escalated to 180 mg once daily after seven days, 2% (1/50) had such events.

Data from the Phase 1/2 trial and pivotal ALTA trial of brigatinib have been included in the NDA submitted to the FDA. The FDA has granted ARIAD’s request for Priority Review and has set an action date of April 29, 2017 under the Prescription Drug User Fee Act (PDUFA). ARIAD is seeking accelerated U.S. marketing approval for brigatinib in patients with metastatic ALK+ NSCLC who are resistant or intolerant to crizotinib and plans to submit a Marketing Authorization Application (MAA) for brigatinib to the European Medicines Agency (EMA) in early 2017.

“This in-depth publication provides a thorough review of the Phase 1/2 trial of brigatinib, ARIAD’s internally developed targeted cancer candidate under regulatory review,” stated Timothy P. Clackson, Ph.D., president of research and development and chief scientific officer at ARIAD. “We are excited to continue to work with academic collaborators to provide additional clinical detail on the brigatinib trials, including upcoming presentations at the World Conference on Lung Cancer in December.”



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News, FDA

Related Entities

Twitter, PDUFA

Add Your Comment